NASDAQ · SION
Healthcare · Biotechnology
$3.73
Down-$0.08 (-2.26%)
Updated Nov 3, 2026, 8:22 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SION
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
SION closed at $3.73 after 21 trading sessions, down 23.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $3.91 | $3.935 | $3.65 | $3.73 | 656.79K |
| Oct 30, 2026 | $3.96 | $4.0499 | $3.76 | $3.87 | 534.38K |
| Oct 29, 2026 | $4.05 | $4.16 | $3.97 | $4.00 | 578.36K |
| Oct 28, 2026 | $3.85 | $4.155 | $3.78 | $4.04 | 953K |
| Oct 27, 2026 | $3.68 | $3.905 | $3.63 | $3.87 | 1M |
| Oct 26, 2026 | $3.58 | $3.74 | $3.57 | $3.69 | 614.22K |
| Oct 23, 2026 | $3.75 | $3.816 | $3.55 | $3.60 | 918.2K |
| Oct 22, 2026 | $3.87 | $3.97 | $3.6414 | $3.80 | 1.59M |
| Oct 21, 2026 | $4.20 | $4.31 | $3.86 | $3.87 | 1.56M |
| Oct 20, 2026 | $4.06 | $4.30 | $4.02 | $4.15 | 1.07M |
| Oct 19, 2026 | $3.93 | $4.11 | $3.84 | $4.01 | 1.17M |
| Oct 16, 2026 | $4.06 | $4.06 | $3.775 | $3.89 | 1.49M |
| Oct 15, 2026 | $4.15 | $4.30 | $4.0201 | $4.08 | 944.61K |
| Oct 14, 2026 | $4.30 | $4.40 | $3.9301 | $4.09 | 1.5M |
| Oct 13, 2026 | $4.69 | $4.795 | $4.365 | $4.38 | 790.63K |
| Oct 12, 2026 | $4.89 | $4.93 | $4.675 | $4.69 | 692.61K |
| Oct 9, 2026 | $4.93 | $5.12 | $4.83 | $4.90 | 633.56K |
| Oct 8, 2026 | $4.78 | $4.97 | $4.65 | $4.90 | 915.6K |
| Oct 7, 2026 | $4.68 | $4.87 | $4.61 | $4.82 | 880.22K |
| Oct 6, 2026 | $4.88 | $4.88 | $4.52 | $4.75 | 1.26M |
| Oct 5, 2026 | $4.95 | $4.96 | $4.63 | $4.85 | 1.1M |
The latest Smart Investors Daily articles mentioning SION.
Company
Market Activity
Research & News
SION research
Company profile and research snapshot.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Wedbush | Neutral | — |
| Aug 11, 2026 | Guggenheim | Neutral | — |
| Aug 11, 2026 | Wedbush | Neutral | — |
| Aug 10, 2026 | BTIG | Neutral | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 12, 2026
Sionna Therapeutics, Inc. (SION) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Yahoo · Oct 8, 2026
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in combination with other CFTR modulators across F508del genotype groups demonstrated the potential of NBD1 stabilizer-based combinations to benefit a broad population of people with CF WALTHAM, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-
Yahoo · Sep 17, 2026
Sionna Therapeutics, Inc. (NASDAQ:SION) announced on September 14 that its board approved an approximately 46% workforce reduction as it concentrates development on SION-451 plus SION-2222 for cystic fibrosis. Sionna Therapeutics, Inc. (NASDAQ:SION) ended the second quarter with approximately $268.3 million in cash, cash equivalents, and marketable securities. Management estimates that the workforce reduction, discontinued investment […]
Yahoo · Sep 16, 2026
Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SION.
